top of page

About Our Team

Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world

Matrivax is a biotechnology company developing human vaccines for the prevention and treatment of life-threatening infectious diseases.


Our pipeline includes two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02).


Matrivax is a privately-held company funded by Morningside Investments and based in the biotech hub of Boston, MA.

Our Leadership

bottom of page